Creema Ltd.
Creema Ltd. (4017.T) Financial Performance & Income Statement Overview
Analyze Creema Ltd. (4017.T) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Creema Ltd. (4017.T) Income Statement & Financial Overview
View the income breakdown for Creema Ltd. 4017.T across both annual and quarterly reports.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $697.62M | $561.00M | $603.81M | $644.33M |
| Cost of Revenue | $146.31M | $107.00M | $132.53M | $162.29M |
| Gross Profit | $551.31M | $454.00M | $471.28M | $482.04M |
| Gross Profit Ratio | $0.79 | $0.81 | $0.78 | $0.75 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $478.00M | $441.00M | $472.86M | $464.26M |
| Operating Expenses | $478.00M | $441.00M | $472.86M | $464.26M |
| Total Costs & Expenses | $624.31M | $548.00M | $605.39M | $626.55M |
| Interest Income | $1.18M | $186000.00 | $385000.00 | $12000.00 |
| Interest Expense | $1.05M | $1.19M | $1.28M | $1.39M |
| Depreciation & Amortization | $9.69M | $9.75M | $364000.00 | $9.65M |
| EBITDA | $85.47M | $22.75M | -$1.21M | $29.66M |
| EBITDA Ratio | $0.12 | $0.04 | -$0.002 | $0.05 |
| Operating Income | $73.31M | $13.00M | -$1.57M | $17.77M |
| Operating Income Ratio | $0.11 | $0.02 | -$0.003 | $0.03 |
| Other Income/Expenses (Net) | $1.41M | $1.00M | -$913000.00 | $844000.00 |
| Income Before Tax | $74.72M | $14.00M | -$2.49M | $18.62M |
| Income Before Tax Ratio | $0.11 | $0.02 | -$0.004 | $0.03 |
| Income Tax Expense | $14.27M | $5.00M | -$12.21M | -$5.31M |
| Net Income | $60.45M | $9.00M | $9.72M | $23.93M |
| Net Income Ratio | $0.09 | $0.02 | $0.02 | $0.04 |
| EPS | $8.97 | $1.24 | $1.40 | $3.55 |
| Diluted EPS | $8.97 | $1.34 | $1.44 | $3.54 |
| Weighted Avg Shares Outstanding | $6.74M | $7.28M | $6.95M | $6.73M |
| Weighted Avg Shares Outstanding (Diluted) | $6.74M | $6.74M | $6.75M | $6.77M |
The company's financials show resilient growth, with revenue advancing from $644.33M in Q1 2024 to $697.62M in Q4 2024. Gross profit remained healthy with margins at 79% in Q4 2024 compared to 75% in Q1 2024. Operating income hit $73.31M last quarter, sustaining a consistent 11% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $85.47M. Net income rose to $60.45M, while earnings per share reached $8.97. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan